Skip to main content
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
letter
. 2020 May 3;19(7):102565. doi: 10.1016/j.autrev.2020.102565

Imatinib might constitute a treatment option for lung involvement in COVID-19

David Bernal-Bello a,, Beatriz Jaenes-Barrios b, Alejandro Morales-Ortega a, José Manuel Ruiz-Giardin a, Virginia García-Bermúdez a, Begoña Frutos-Pérez a, Ana Isabel Farfán-Sedano a, Cristina de Ancos-Aracil a, Fernando Bermejo c, Mario García-Gil d, Antonio Zapatero-Gaviria a, Juan Víctor San Martín-López a
PMCID: PMC7252139  PMID: 32376403

Dear Editor,

We have read with interest the comprehensive review regarding interleukin-6 (IL-6) and other pro-inflammatory cytokines in the development of coronavirus disease 2019 (COVID-19) pneumonia [1]. The authors insightfully noted that early initiation of anti-viral therapy to reduce viral load of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) could be helpful in preventing the cytokine storm observed in some of these patients.

In this regard, identifying therapeutic options seems critical to control the outbreak caused by SARS-CoV-2. Antimalarial agents and protease inhibitors have been reported as possible treatments [2,3]. Moreover, inhibition of Janus kinase (JAK) and IL-6 pathways have also been suggested as potential therapies, according to recent data [4,5]. Other possible therapies include the use of corticosteroids, intravenous immunoglobulins or synthetic variants of the interleukin-1 (IL-1) antagonist. However, there is a lack of robust evidence regarding these treatments, which often emanates from in vitro experiences, murine models or series with a limited number of patients. Therefore, understanding the COVID-19 pathogenesis seems key to getting a better therapy and improving the survival rates [6].

Imatinib is an oral anticancer agent that inhibits the activity of some tyrosine kinases, most prominently the BCR-ABL1 fusion oncoprotein (whose overactivation can lead to chronic myeloid leukemia, CML), c-kit (involved in gastrointestinal stromal tumors development), platelet-derived growth factor receptor (PDGFR), and the native ABL1 kinase, who has a ubiquitous expression and plays important roles in several biological processes [7,8].

In addition to the well-known antitumor effect, imatinib has also shown in vitro anti-viral properties against severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), which are phylogenetically related to SARS-CoV-2 [9]. In fact, Coleman et al. [10] showed that imatinib can play an inhibitory role over SARS-CoV and MERS-CoV, especially by blocking the early stages of coronavirus (CoV) infection. Sisk et al. [11] also found that imatinib reduced the titers of infectious bronchitis virus (a viral model for studying the role of tyrosine kinase activity during CoV infection) by interfering with virus–cell fusion. Interestingly, ABL1 inhibitors were also shown to have in vitro activity against other RNA viruses including coxsackievirus [12], hepatitis C virus [13], or Ebola virus [14], among others, mainly through blocking viral entry or egress from the host cell.

Moreover, evidence suggests that imatinib might modulate the immune response. In fact, this drug has been reported as arthritis suppressor and inhibitor of IL-6 and other pro-inflammatory cytokines according to murine models [15,16]. In this regard, positive effects have been observed lowering inflammation in patients diagnosed with rheumatoid arthritis [[17], [18], [19]], asthma [20] and other chronic inflammatory disorders such as Crohn's disease [21,22] and refractory eosinophilic granulomatosis with polyangiitis [23]. Likewise, imatinib has been linked to improving pulmonary endothelial barrier dysfunction and edema observed in acute lung injury and sepsis [24,25].

Imatinib might play its potentially beneficial immunomodulatory role in COVID-19 patients by several mechanisms. This drug can reduce the transcription factor NF-κB signaling pathway, as demonstrated by Rizzo et al. [26] both in vitro (in lipopolysaccharide (LPS)-stimulated human pulmonary artery endothelial cells) and in murine model of acute lung injury. NF-κB is often targeted by pathogens to maintain their life cycle within the host cell and seems to be activated in patients with CoV infection [27,28]. It has also been suggested that imatinib stimulates prostaglandin E2 (which is related to a prominent protective role in the airways) and attenuates cytokine release by activating its receptor EP4, leading to a less pronounced increase of tumor necrosis factor-α (TNF-α), IL1-β and IL-6 in LPS-stimulated blood of patients treated with this drug compared with the cytokine response to LPS in healthy controls [29]. Similar outcomes regarding imatinib reducing TNF-α and IL-6 production in sepsis-induced adult respiratory distress syndrome murine models have been reported [30,31]. These findings could also contribute to explain the observation of a significant down-regulation of NF-κB, IL-6 and other pro-inflammatory cytokines release in lymphomonocytes from CML imatinib-treated patients [32].

Oral absorption of imatinib can be considered optimal, its mean bioavailability reaches 98% and the terminal elimination half-life has been estimated at approximately 18 h [33]. It can be dissolved in water for patients having difficulty swallowing or for those who need a nasogastric tube. Furthermore, this drug is well tolerated and the risk of severe adverse effects is relatively low, especially in short-term administration [34]. It is also recognized that adverse effects, mostly mild to moderate in intensity, will be easily controlled by dose reduction or discontinuation [35]. Additionally, imatinib seems an admissible treatment from an economic point of view and its availability in hospitals is usually high.

In summary, taking into account the potential role of imatinib as antiviral and immunomodulatory agent in addition to an acceptable safety profile, we believe that this drug should be explored as a treatment option for COVID-19 pneumonia.

Contributor Information

David Bernal-Bello, Email: david.bernal@salud.madrid.org.

Beatriz Jaenes-Barrios, Email: beatriz.jaenes@salud.madrid.org.

Alejandro Morales-Ortega, Email: alejandro.morales@salud.madrid.org.

José Manuel Ruiz-Giardin, Email: josemanuel.ruiz@salud.madrid.org.

Virginia García-Bermúdez, Email: vgbermudez@salud.madrid.org.

Begoña Frutos-Pérez, Email: begona.frutos@salud.madrid.org.

Ana Isabel Farfán-Sedano, Email: anai.farfan@salud.madrid.org.

Cristina de Ancos-Aracil, Email: cristina.ancos@salud.madrid.org.

Fernando Bermejo, Email: fernando.bermejo@salud.madrid.org.

Mario García-Gil, Email: mgarciagil@salud.madrid.org.

Antonio Zapatero-Gaviria, Email: antonio.zapatero@salud.madrid.org.

Juan Víctor San Martín-López, Email: juanvictor.san@salud.madrid.org.

References

  • 1.McGonagle D., Sharif K., O’Regan A., Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev. 2020 doi: 10.1016/j.autrev.2020.102537. published online April 3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Yao X., Ye F., Zhang M. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Clin Infect Dis. 2020 doi: 10.1093/cid/ciaa237. published online March 9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Yao T., Qian J., Zhu W., Wang Y., Wang G. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—a possible reference for coronavirus disease-19 treatment option. J Med Virol. 2020 doi: 10.1002/jmv.25729. published online February 27. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Richardson P., Griffin I., Tucker C. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395:e30–e31. doi: 10.1016/S0140-6736(20)30304-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Mehta P., McAuley D.F., Brown M. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020 doi: 10.1016/S0140-6736(20)30628-0. published online March 16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Shoenfeld Y. Corona (COVID-19) time musings: Our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning. Autoimmun Rev. 2020 doi: 10.1016/j.autrev.2020.102538. published online April 5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Shaul Y. c-Abl: activation and nuclear targets. Cell Death Differ. 2000;7:10–16. doi: 10.1038/sj.cdd.4400626. [DOI] [PubMed] [Google Scholar]
  • 8.Iqbal N., Iqbal N. Imatinib: a breakthrough of targeted therapy in cancer. Chemother Res Pract. 2014;2014:357027. doi: 10.1155/2014/357027. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Lu R., Zhao X., Li J. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565–574. doi: 10.1016/S0140-6736(20)30251-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Coleman C.M., Sisk J.M., Mingo R.M., Nelson E.A., White J.M., Frieman M.B. Abelson kinase inhibitors are potent inhibitors of Severe Acute Respiratory Syndrome coronavirus and Middle East Respiratory Syndrome coronavirus fusion. J Virol. 2016;90:8924–8933. doi: 10.1128/JVI.01429-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Sisk J.M., Frieman M.B., Machamer C.E. Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors. J Gen Virol. 2018;99:619–630. doi: 10.1099/jgv.0.001047. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Coyne C.B., Bergelson J.M. Virus-induced Abl and Fyn kinase signals permit coxsackievirus entry through epithelial tight junctions. Cell. 2006;124:119–131. doi: 10.1016/j.cell.2005.10.035. [DOI] [PubMed] [Google Scholar]
  • 13.Min S., Lim Y.S., Shin D. Abl tyrosine kinase regulates hepatitis C virus entry. Front Microbiol. 2017;8:1129. doi: 10.3389/fmicb.2017.01129. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Garcia M., Cooper A., Shi W. Productive replication of ebola virus is regulated by the c-Abl1 tyrosine kinase. Sci Transl Med. 2012;4:123ra24. doi: 10.1126/scitranslmed.3003500. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Akashi N., Matsumoto I., Tanaka Y. Comparative suppressive effects of tyrosine kinase inhibitors imatinib and nilotinib in models of autoimmune arthritis. Mod Rheumatol. 2011;21:267–275. doi: 10.1007/s10165-010-0392-5. [DOI] [PubMed] [Google Scholar]
  • 16.Paniagua R.T., Sharpe O., Ho P.P. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest. 2006;116:2633–2642. doi: 10.1172/JCI28546. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Pereira I., Fialho S., Castro G., Zimmermann A. Imatinib mesylate induces clinical remission in rheumatoid arthritis. Jt Bone Spine. 2010;77:372–373. doi: 10.1016/j.jbspin.2010.03.014. [DOI] [PubMed] [Google Scholar]
  • 18.Eklund K.K., Lindstedt K., Sandler C. Maintained efficacy of the tyrosine kinase inhibitor imatinib mesylate in a patient with rheumatoid arthritis. J Clin Rheumatol. 2008;14:294–296. doi: 10.1097/RHU.0b013e318188b1ce. [DOI] [PubMed] [Google Scholar]
  • 19.Vernon M.R., Pearson L., Atallah E. Resolution of rheumatoid arthritis symptoms with imatinib mesylate. J Clin Rheumatol. 2009;15:267. doi: 10.1097/RHU.0b013e3181b0d352. [DOI] [PubMed] [Google Scholar]
  • 20.Cahill K.N., Katz H.R., Cui J. KIT inhibition by imatinib in patients with severe refractory asthma. N Engl J Med. 2017;376:1911–1920. doi: 10.1056/NEJMoa1613125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Magro F., Costa C. Long-standing remission of Crohn’s disease under imatinib therapy in a patient with Crohn’s disease. Inflamm Bowel Dis. 2006;12:1087–1089. doi: 10.1097/01.mib.0000232468.15950.34. [DOI] [PubMed] [Google Scholar]
  • 22.De Backer O., Lefebvre R.A. Is there a role for imatinib in inflammatory bowel disease? Inflamm Bowel Dis. 2008;14:579–581. doi: 10.1002/ibd.20320. [DOI] [PubMed] [Google Scholar]
  • 23.Beketova T.V., Volkov M.Y., Naryshkin E.A., Novoselova T.M., Nasonov E.L. Imatinib mesylate use in refractory eosinophilic granulomatosis with polyangiitis: a literature review and a case report. Clin Rheumatol. 2018;37:1729–1735. doi: 10.1007/s10067-018-4018-1. [DOI] [PubMed] [Google Scholar]
  • 24.Chislock E.M., Pendergast A.M. Abl family kinases regulate endothelial barrier function in vitro and in mice. PLoS One. 2013;8 doi: 10.1371/journal.pone.0085231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Aman J., Van Bezu J., Damanafshan A. Effective treatment of edema and endothelial barrier dysfunction with imatinib. Circulation. 2012;126:2728–2738. doi: 10.1161/CIRCULATIONAHA.112.134304. [DOI] [PubMed] [Google Scholar]
  • 26.Rizzo A.N., Sammani S., Esquinca A.E. Imatinib attenuates inflammation and vascular leak in a clinically relevant two-hit model of acute lung injury. Am J Physiol Cell Mol Physiol. 2015;309:L1294–L1304. doi: 10.1152/ajplung.00031.2015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Dosch S.F., Mahajan S.D., Collins A.R. SARS coronavirus spike protein-induced innate immune response occurs via activation of the NF-κB pathway in human monocyte macrophages in vitro. Virus Res. 2009;142:19–27. doi: 10.1016/j.virusres.2009.01.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Guo Y.-R., Cao Q.-D., Hong Z.-S. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020;7:11. doi: 10.1186/s40779-020-00240-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Bärnthaler T., Jandl K., Sill H. Imatinib stimulates prostaglandin E2 and attenuates cytokine release via EP4 receptor activation. J Allergy Clin Immunol. 2019;143 doi: 10.1016/j.jaci.2018.09.030. 794-797.e10. [DOI] [PubMed] [Google Scholar]
  • 30.Letsiou E., Rizzo A.N., Sammani S. Differential and opposing effects of imatinib on LPS- and ventilator-induced lung injury. Am J Physiol Lung Cell Mol Physiol. 2015;308:L259–L269. doi: 10.1152/ajplung.00323.2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Stephens R.S., Johnston L., Servinsky L., Kim B.S., Damarla M. The tyrosine kinase inhibitor imatinib prevents lung injury and death after intravenous LPS in mice. Physiol Rep. 2015;3 doi: 10.14814/phy2.12589. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Ciarcia R., Vitiello M.T., Galdiero M. Imatinib treatment inhibit IL-6, IL-8, NF-KB and AP-1 production and modulate intracellular calcium in CML patients. J Cell Physiol. 2012;227:2798–2803. doi: 10.1002/jcp.23029. [DOI] [PubMed] [Google Scholar]
  • 33.Peng B., Lloyd P., Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44:879–894. doi: 10.2165/00003088-200544090-00001. [DOI] [PubMed] [Google Scholar]
  • 34.Steegmann J.L., Baccarani M., Breccia M. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30:1648–1671. doi: 10.1038/leu.2016.104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Mughal T.I., Schrieber A. Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase. Biologics. 2010;4:315–323. doi: 10.2147/BTT.S5775. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Autoimmunity Reviews are provided here courtesy of Elsevier

RESOURCES